1
|
Shepherd F, Houdijk JGM, Chylinski C, Hutchings MR, Kelly RF, Macrae A, Maurer V, Salminen JP, Engström MT, Athanasiadou S. The feeding of heather (Calluna vulgaris) to Teladorsagia circumcincta infected lambs reduces parasitism but can detrimentally impact performance. Vet J 2024; 303:106066. [PMID: 38244671 DOI: 10.1016/j.tvjl.2024.106066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 01/08/2024] [Accepted: 01/11/2024] [Indexed: 01/22/2024]
Abstract
Gastrointestinal nematode (GIN) infections impact small ruminant health, welfare, and production across farming systems. Rising anthelmintic resistance and regulation of synthetic drug use in organic farming is driving research and development of sustainable alternatives for GIN control. One alternative is the feeding of plants that contain secondary metabolites (PSMs) e.g., proanthocyanidins (PA, syn. condensed tannins) that have shown anthelmintic potential. However, PSMs can potentially impair performance, arising from reduced palatability and thus intake, digestibility or even toxicity effects. In this study, we tested the trade-off between the antiparasitic and anti-nutritional effects of heather consumption by lambs. The impact of additional feeding of a nematophagous fungus (Duddingtonia flagrans) on larval development was also explored. Lambs infected with Teladorsagia circumcincta or uninfected controls, were offered ad libitum heather, or a control chopped hay for 22 days during the infection patent period. Eight days into the patent period, parasitised lambs were supplemented (or remained unsupplemented) with D. flagrans for a 5-day period. Performance and infection metrics were recorded, and polyphenol levels in the heather and control hay were measured to investigate their association with activity. The lambs consumed heather at approximately 20% of their dry matter intake, which was sufficient to exhibit significant anthelmintic effects via a reduction in total egg output (P = 0.007), compared to hay-fed lambs; the magnitude of the reduction over time in heather fed lambs was almost 10-fold compared to control lambs. Negative effects on production were shown, as heather-fed lambs weighed 6% less than hay-fed lambs (P < 0.001), even though dry matter intake (DMI) of heather increased over time. D. flagrans supplementation lowered larval recovery in the faeces of infected lambs by 31.8% (P = 0.003), although no interactions between feeding heather and D. flagrans were observed (P = 0.337). There was no significant correlation between PA, or other polyphenol subgroups in the diet and egg output, which suggests that any association between heather feeding and anthelmintic effect is not simply and directly attributable to the measured polyphenols. The level of heather intake in this study showed no antagonistic effects on D. flagrans, demonstrating the methods can be used in combination, but provide no additive effect on overall anthelmintic efficacies. In conclusion, heather feeding can assist to reduce egg outputs in infected sheep, but at 20% of DMI negative effects on lamb performance can be expected which may outweigh any antiparasitic benefits.
Collapse
Affiliation(s)
- F Shepherd
- Scotland's Rural College SRUC, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom; Royal Dick School of Veterinary Studies R(D)SVS and the Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - J G M Houdijk
- Scotland's Rural College SRUC, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - C Chylinski
- Scotland's Rural College SRUC, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - M R Hutchings
- Scotland's Rural College SRUC, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - R F Kelly
- Royal Dick School of Veterinary Studies R(D)SVS and the Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - A Macrae
- Royal Dick School of Veterinary Studies R(D)SVS and the Roslin Institute, University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - V Maurer
- Research Institute of Organic Agriculture FiBL, Ackerstrasse 113, CH-5070 Frick, Switzerland
| | - J-P Salminen
- University of Turku, Department of Chemistry (Aurum), Henrikinkatu 2, FI-20500 Turku, Finland
| | - M T Engström
- University of Turku, Department of Chemistry (Aurum), Henrikinkatu 2, FI-20500 Turku, Finland
| | - S Athanasiadou
- Scotland's Rural College SRUC, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom.
| |
Collapse
|
2
|
Sugumar V, Sr RRS, Ye XY, Zhan L, Sun A, Bezjak A, Cho J, Raman S, Hope AJ, Giuliani ME, Leighl N, Sacher AG, Shepherd F, Bradbury P, Liu G, Lok BH. Survival Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated with Consolidative Thoracic Radiotherapy at a Tertiary Cancer Center. Int J Radiat Oncol Biol Phys 2023; 117:e60. [PMID: 37785810 DOI: 10.1016/j.ijrobp.2023.06.779] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Most small cell lung cancer cases present as Stage IV (M1) or extensive stage (ES-SCLC), which are defined as tumor extending outside the hemithorax without a tolerable radiation portal. The CREST trial demonstrated improved local control with a modest overall survival (OS) benefit at the 2-year secondary endpoint of 14% survival with consolidative thoracic radiotherapy (CTRT) compared to 3% without CTRT. Low toxicity rates were also observed. This study reports our institutional ES-SCLC experience for patients treated with CTRT. MATERIALS/METHODS A retrospective review was conducted on ES-SCLC patients treated with CTRT at our institution between 2014 and 2019. CTRT was defined as ≥30 Gy of thoracic radiotherapy. OS and tolerability of treatment were assessed in this population. Chemotherapy details were also captured. OS rate was determined using the Kaplan-Meier method and the time from start of CTRT to last date of follow-up or death. CTRT tolerability was determined using incidence and grade of esophagitis and radiation pneumonitis as per CTCAE v5. RESULTS We identified 100 ES-SCLC patients treated with any thoracic RT at our institute, of which 45 received thoracic RT for palliative intent or with <30 Gy. The remaining 55 patients received ≥30 Gy CTRT and were included for analysis. The median age was 65.1 years (range 46.6-86.9) and 36 (65%) were male. The median follow-up for this sample was 0.8 (range 0.03-4.2) years. Median chemotherapy cycles were 6 (range 1-6), most receiving ≥4 cycles (87%) and completing chemotherapy prior to CTRT initiation (91%) with a minority concurrently receiving chemotherapy and CTRT (9%). Platinum chemotherapy was the most common (96%) with 2 patients receiving etoposide alone (4%). The most common CTRT regimens were 30 Gy in 10 fractions (80%) followed by 40 Gy in 15 fractions (9%) and 45 Gy in 30 twice-daily fractions (7%). Most patients (67%) were treated with IMRT/VMAT technique, while the remaining (33%) patients were treated with 3DCRT. The median survival time was 1.3 years with 1- and 2-year OS of 57.2% (CI 44.0 - 74.3%) and 26.1% (CI 12.9 - 52.7%), respectively. CTRT was well tolerated with no grade 4+ toxicities. The most common toxicity was esophagitis with 21 patients (39%), of which 15 were G1 (28%) and 6 were G2 (11%). Radiation pneumonitis was present in 5 patients (9.2%) with 1 G1 (2%), 3 G2 (6%), and 1 G3 (2%) cases. CONCLUSION Consolidative TRT for ES-SCLC in this institutional series was at least as good as the reported CREST outcome with modest acute toxicities in this cohort. Disease burden at diagnosis, chemotherapy response, patterns of failure, and subsequent therapies will be further investigated.
Collapse
Affiliation(s)
- V Sugumar
- Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - R R Salunkhe Sr
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - X Y Ye
- Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - L Zhan
- Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - A Sun
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - A Bezjak
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - J Cho
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - S Raman
- Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
| | - A J Hope
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - M E Giuliani
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| | - N Leighl
- Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
| | - A G Sacher
- Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
| | - F Shepherd
- Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
| | - P Bradbury
- Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
| | - G Liu
- Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
| | - B H Lok
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
3
|
Thaweethai T, Jolley SE, Karlson EW, Levitan EB, Levy B, McComsey GA, McCorkell L, Nadkarni GN, Parthasarathy S, Singh U, Walker TA, Selvaggi CA, Shinnick DJ, Schulte CCM, Atchley-Challenner R, Alba GA, Alicic R, Altman N, Anglin K, Argueta U, Ashktorab H, Baslet G, Bassett IV, Bateman L, Bedi B, Bhattacharyya S, Bind MA, Blomkalns AL, Bonilla H, Bush PA, Castro M, Chan J, Charney AW, Chen P, Chibnik LB, Chu HY, Clifton RG, Costantine MM, Cribbs SK, Davila Nieves SI, Deeks SG, Duven A, Emery IF, Erdmann N, Erlandson KM, Ernst KC, Farah-Abraham R, Farner CE, Feuerriegel EM, Fleurimont J, Fonseca V, Franko N, Gainer V, Gander JC, Gardner EM, Geng LN, Gibson KS, Go M, Goldman JD, Grebe H, Greenway FL, Habli M, Hafner J, Han JE, Hanson KA, Heath J, Hernandez C, Hess R, Hodder SL, Hoffman MK, Hoover SE, Huang B, Hughes BL, Jagannathan P, John J, Jordan MR, Katz SD, Kaufman ES, Kelly JD, Kelly SW, Kemp MM, Kirwan JP, Klein JD, Knox KS, Krishnan JA, Kumar A, Laiyemo AO, Lambert AA, Lanca M, Lee-Iannotti JK, Logarbo BP, Longo MT, Luciano CA, Lutrick K, Maley JH, Marathe JG, Marconi V, Marshall GD, Martin CF, Matusov Y, Mehari A, Mendez-Figueroa H, Mermelstein R, Metz TD, Morse R, Mosier J, Mouchati C, Mullington J, Murphy SN, Neuman RB, Nikolich JZ, Ofotokun I, Ojemakinde E, Palatnik A, Palomares K, Parimon T, Parry S, Patterson JE, Patterson TF, Patzer RE, Peluso MJ, Pemu P, Pettker CM, Plunkett BA, Pogreba-Brown K, Poppas A, Quigley JG, Reddy U, Reece R, Reeder H, Reeves WB, Reiman EM, Rischard F, Rosand J, Rouse DJ, Ruff A, Saade G, Sandoval GJ, Schlater SM, Shepherd F, Sherif ZA, Simhan H, Singer NG, Skupski DW, Sowles A, Sparks JA, Sukhera FI, Taylor BS, Teunis L, Thomas RJ, Thorp JM, Thuluvath P, Ticotsky A, Tita AT, Tuttle KR, Urdaneta AE, Valdivieso D, VanWagoner TM, Vasey A, Verduzco-Gutierrez M, Wallace ZS, Ward HD, Warren DE, Weiner SJ, Welch S, Whiteheart SW, Wiley Z, Wisnivesky JP, Yee LM, Zisis S, Horwitz LI, Foulkes AS. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA 2023; 329:1934-1946. [PMID: 37278994 PMCID: PMC10214179 DOI: 10.1001/jama.2023.8823] [Citation(s) in RCA: 152] [Impact Index Per Article: 152.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Accepted: 05/01/2023] [Indexed: 06/07/2023]
Abstract
Importance SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals. Objective To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections. Design, Setting, and Participants Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling. Exposure SARS-CoV-2 infection. Main Outcomes and Measures PASC and 44 participant-reported symptoms (with severity thresholds). Results A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months. Conclusions and Relevance A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC.
Collapse
Affiliation(s)
- Tanayott Thaweethai
- Massachusetts General Hospital, Boston
- Harvard Medical School, Boston, Massachusetts
| | | | | | | | - Bruce Levy
- Harvard Medical School, Boston, Massachusetts
- Brigham and Women's Hospital, Boston, Massachusetts
| | | | - Lisa McCorkell
- Patient-Led Research Collaborative, Calabasas, California
| | | | | | - Upinder Singh
- Stanford University School of Medicine, Stanford, California
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Mario Castro
- University of Kansas Medical Center, Kansas City
| | | | | | - Peter Chen
- Cedars-Sinai Medical Center, Los Angeles, California
| | | | - Helen Y Chu
- University of Washington School of Medicine, Seattle
| | | | | | | | | | | | | | | | | | | | | | | | - Cheryl E Farner
- The University of Texas Health Science Center at San Antonio
| | | | | | - Vivian Fonseca
- Tulane University Health Sciences Center, New Orleans, Louisiana
| | | | | | | | | | | | | | - Minjoung Go
- Stanford University School of Medicine, Stanford, California
| | | | | | | | | | - John Hafner
- University of Illinois Chicago College of Medicine
| | - Jenny E Han
- Emory University School of Medicine, Atlanta, Georgia
| | | | - James Heath
- Institute for Systems Biology, Seattle, Washington
| | | | - Rachel Hess
- University of Utah Schools of the Health Sciences, Salt Lake City
| | - Sally L Hodder
- West Virginia Clinical and Translational Science Institute, Morgantown
| | | | | | | | | | | | - Janice John
- Cambridge Health Alliance, Cambridge, Massachusetts
| | | | - Stuart D Katz
- New York University Grossman School of Medicine, New York
| | | | | | - Sara W Kelly
- University of Illinois College of Medicine at Peoria
| | | | - John P Kirwan
- Pennington Biomedical Research Center, Baton Rouge, Louisiana
| | | | | | - Jerry A Krishnan
- University of Illinois Hospital and Health Sciences System, Chicago
| | - Andre Kumar
- Stanford University School of Medicine, Stanford, California
| | | | | | | | | | | | | | | | | | - Jason H Maley
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | | | | | | | | | - Yuri Matusov
- Cedars-Sinai Medical Center, Los Angeles, California
| | - Alem Mehari
- Howard University College of Medicine, Washington, DC
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Jan E Patterson
- The University of Texas Health Science Center at San Antonio
| | | | | | | | | | | | - Beth A Plunkett
- Harvard Medical School, Boston, Massachusetts
- NorthShore University HealthSystem, Evanston, Illinois
| | | | - Athena Poppas
- Warren Alpert Medical School, Brown University, Providence, Rhode Island
| | | | - Uma Reddy
- Columbia University Irving Medical Center, New York, New York
| | - Rebecca Reece
- West Virginia University School of Medicine, Morgantown
| | | | - W B Reeves
- Department of Medicine, The University of Texas Health Science Center at San Antonio
| | | | | | | | | | - Adam Ruff
- The University of Kansas Medical Center, Kansas City
| | | | - Grecio J Sandoval
- Milken Institute of Public Health, The George Washington University, Washington, DC
| | | | | | - Zaki A Sherif
- Howard University College of Medicine, Washington, DC
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Steven J Weiner
- The George Washington University Biostatistics Center, Rockville, Maryland
| | | | | | | | | | - Lynn M Yee
- Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | | | | | - Andrea S Foulkes
- Massachusetts General Hospital, Boston
- Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
4
|
O'Kane G, Leon A, Shabir M, Law J, Bradbury P, Liu G, Sacher A, Shepherd F, Torti D, Stockley T, Tsao M, Pugh T, Leighl N. P35.03 Methylation Signatures Associated with T790M Status in Progressive NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Lau S, Soleimani S, Wong S, Wang B, Pedersen S, Patel D, Bradbury P, Liu G, Leighl N, Tsao M, Siu L, Bratman S, Ohashi P, Pugh T, Shepherd F, Sacher A. P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Chowdhury M, Hueniken K, Schmid S, Brown C, Khan K, Walia P, Sabouhanian A, Strom E, Herman J, Xu W, Leighl N, Bradbury P, Sacher A, Shepherd F, Liu G, Shultz D. P76.84 EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Wu Y, John T, Grohe C, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.292] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Lam A, Aggarwal R, Huang J, Hueniken K, Tsao M, Shepherd F, Xu W, Kavanagh J, Liu G. PR01.07 Predicting Changes in Lung Cancer Risk in the At-Risk Screen Ineligible Population. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Laurie S, Agulnik J, Hao D, Juergens R, Ezeife D, Law J, Le L, Kiedrowski L, Shepherd F, Cohen V, Melosky B, Vandermeer R, Wheatley-Price P, Lanman R, Leighl N, Laskin J. 1195P The value of detecting resistance through liquid biopsy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Schmid S, Schouwenburg S, Stewart E, Fares A, Bradbury P, Shepherd F, Leighl N, Sacher A, Patel D, Li X, Xu W, Liu G. 1217P Breathomics eNose technology as a non-invasive, inexpensive, point-of-care predictive test to detect early stage lung cancer in never or former light smokers. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1419] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Martins-Filho S, Fares A, Raghavan V, Stewart E, Ravi D, Perdrizet K, Weiss J, Hueniken K, Patel D, Pham N, Sacher A, Bradbury P, Leighl N, Shepherd F, Tsao M, Liu G. P2.03-11 Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Stewart E, Martins-Filho S, Cabanero M, Wang A, Huang J, Bao H, Wu X, Patel D, Chen Z, Law J, Bradbury P, Shepherd F, Leighl N, Tsao M, Pugh T, Bratman S, Liu G, Sacher A. P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Santoro A, Garrido Lopez P, Tan D, Paz-Ares L, Shepherd F, Bearz A, Barlesi F, Vansteenkiste J, Kim T, Overbeck T, Rybkin I, Felip E, Zhou W, Santarpia L, Eddy S, Schaefer E. Preliminary results from phase Ib study of spartalizumab plus chemotherapy for advanced non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Eng L, Su J, Hueniken K, Brown M, Hope A, Bezjak A, Sacher A, Bradbury P, Shepherd F, Leighl N, Pierre A, Selby P, Goldstein D, Xu W, Giuliani M, Evans W, Liu G, Chaiton M. P1.10-05 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
15
|
Lau S, Le L, Chan S, Smith E, Ryan M, Brown M, Hueniken K, Eng L, Patel D, Chen R, Sung M, Zer A, Bradbury P, Ohashi P, Shepherd F, Tsao M, Leighl N, Liu G, Sacher A. P1.01-70 Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Wells J, Sidhu A, Ding K, Heng D, Shepherd F, Ellis P, Bradbury P, Jonker D, Moore M, Siu L, Gelmon K, Karapetis C, Shapiro J, Nott L, O’Callaghan C, Parulekar W, Seymour L, Smoragiewicz M, Monzon J. Complementary medicine (CM) use in phase III clinical trials (P3T) conducted by the Canadian Cancer Trials Group (CCTG). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
17
|
Bueno R, Harpole D, Tsao M, Beer D, Watson M, Shepherd F, Richards W, Ballman K, Wang X, Chen Z, Govindan R, Chen G, Rivard C, Hirsch F. OA13.01 SPECS2 Lung Cancer Consortium Prospective Multicenter Validation of Prognostic Signature for Early Stage Squamous Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
18
|
Perdrizet K, Stockley T, Law J, Shabir M, Zhang T, Le L, Lau A, Tsao M, Kamel-Reid S, Pal P, Cabanero M, Schwock J, Ko H, Liu G, Bradbury P, Sacher A, Shepherd F, Leighl N. P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Moraes F, Weiss J, Moskovitz M, Sorotsky H, Pintilie M, Leighl N, Bradbury P, Liu G, Zadeh G, Doherty M, Kia A, So J, Cabanero M, Pugh T, Sugumar V, Torti D, Tsao M, Torchia J, Shultz D, Shepherd F, Lok B. MA25.11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
20
|
Perdrizet K, Stockley T, Tsao M, Morganstein J, Kamel-Reid S, Ranich L, Shepherd F, Bradbury P, Liu G, Hwang D, Pal P, Schwock J, Boerner S, Sacher A, Law J, Leighl N. P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
21
|
Ezeife D, Morganstein J, Lau S, Law J, Le L, Bradbury P, Liu G, Shepherd F, Leighl N. MA14.06 Predictors of Financial Toxicity, an Under-Recognized Patient-Reported Outcome. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Tokar T, Pastrello C, Ramnarine V, Zhu C, Craddock K, Pikor L, Vucic E, Vary S, Shepherd F, Tsao M, Lam W, Jurisica I. P3.03-06 Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
23
|
Jiang S, Hurry M, Hueniken K, Brown M, Liang M, Patel D, Labbe C, Eng L, Naik H, Bradbury P, Leighl N, Shepherd F, Xu W, Liu G, Walton R, O'Kane G. MA18.09 Predictors of Health Utility Scores (HUS) in Advanced EGFR-Mutated NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.471] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Martins-Filho S, Cabanero M, Pham N, Stewart E, Ravi D, Patel D, Mcconnell J, Grindlay A, Allison F, Li M, Shepherd F, Tsao M, Yasufuku K, Liu G. MA27.01 Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
25
|
Eng L, Liu S, Farzanfar D, Alton D, Smith E, Mccartney A, Yeung S, Basgaran A, Balaratnam K, Mattina K, Harper C, Mohan R, Brown M, Hope A, Bradbury P, Sacher A, Leighl N, Shepherd F, Bezjak A, Howell D, Jones J, Xu W, Goldstein D, Evans W, Selby P, Giuliani M, Liu G. MA18.07 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Shepherd F. MS21.04 Targeted Therapy - The Second Revolution. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
27
|
Hueniken K, Hurry M, Jiang S, Labbe C, Brown M, Eng L, Naik H, Liang M, Patel D, Bradbury P, Leighl N, Shepherd F, Xu W, O'Kane G, Walton R, Liu G. P1.13-11 PRO-CTCAE Toxicities in Advanced NSCLC Patients with EGFR Mutations: A Real World Assessment. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
28
|
Sequist L, Gray J, Harb W, Doebele R, Modiano M, Jackman D, Baggstrom M, Atmaca A, Felip E, Provencio M, Cobo Dols M, Adiwijaya B, Kuesters G, Kamoun W, Andreas K, Pipas J, Santillana S, Cho B, Park K, Shepherd F. P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Sung M, Zer A, Walia P, Khoja L, Maganti M, Labbe C, Shepherd F, Bradbury P, Liu G, Leighl N. P3.04-20 Correlation of Immune-Related Adverse Events and Response from Immune Checkpoint Inhibitors in Patients with Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1727] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
30
|
Yu H, Chen Z, Ballman K, Watson M, Govindan R, Beer D, Bueno R, Herman M, Franklin W, Gandara D, Joshi M, Merrick D, Richards W, Rivard C, Shepherd F, Tsao M, Bokhoven A, Harpole D, Hirsch F. P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Moghal N, Pham N, Shi R, Radulovich N, Li M, Raghavan V, Li Q, Wang D, Tong J, Zhu C, Li L, Stewart E, Tamblyn L, Weiss J, Martins-Filho S, Ravi D, Pintilie M, Moran M, Liu G, Leighl N, Shepherd F, Tsao M. MTE01.02 Lung Patient Derived Xenograft and Organoid. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Antonia S, Gettinger S, Borghaei H, Goldman J, Brahmer J, Ready N, Gerber D, Chow L, Juergens R, Laurie S, Shepherd F, Li X, Li A, Geese W, Hellmann M. P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.558] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Carcereny E, Felip E, Reck M, Patel J, Heist R, Balmanoukian A, Chow L, Paz-Ares L, Qiu J, Coleman S, Mocci S, Sandler A, Kurata T, Shepherd F. OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.428] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
34
|
Reck M, Shepherd F, Pérol M, Cappuzzo F, Shih J, Park K, Winfree K, Alexandris E, Lee P, Sashegyi A, Garon E. MA 03.06 Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.464] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Hao D, Sengupta A, Ding K, Leighl N, Shepherd F, Seymour L, Weljie A. P2.01-055 Examining Metabolomics as a Prognostic Marker in Metastatic Non–Small Cell Lung Cancer Patients Undergoing First-Line Chemotherapy. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Sequist L, Anderson I, Bauer T, Demars N, Felip E, Frost N, Harb W, Horn L, Huber R, Kudla A, Lee J, Mathews S, Mehra R, Nieva J, Perol M, Shepherd F, Spira A, Czibere A. A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.96] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
37
|
Zer A, Hershko-Klement A, Hwang D, Korpanty G, Leighl N, Liu G, Feld R, Burkes R, Tsao M, Shepherd F. 176P: ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30286-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Yau V, Giuliani M, Wong O, Le L, Darling G, Shepherd F, Brade A, Cho J, Sun A, Bezjak A, Hope A. Outcomes in Patients With Stage III Non-Small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemotherapy and Radiation Therapy Followed by Surgical Resection. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
Seymour L, Le Teuff G, Tsao M, Brambilla E, Shepherd F, Soria J, Kratzke R, Graziano S, Douillard J, Rosell R, Reiman A, Lacas B, Bourredjem A, Le Chevalier T, Pirker R, Filipits M, Hainaut P, Janne P, Pignon J. Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Ellis P, Liu G, Millward M, Perrone F, Shepherd F, Seymour L, Sun S, Cho B, Morabito A, Stockler M, Leighl N, Lee C, Wierzbicki R, Favaretto A, Tsao M, Wilson C, Taylor I, Ding K, Goss G, Bradbury P. The Relationship Between Egfr and Kras Mutation Status and Overall Survival (Os) in the Ncic Ctg Br.26 Randomized Trial of Dacomitinib (D) Versus Placebo (P) in Patients with Previously Treated Non Small Cell Lung Cancer (Nsclc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Darling G, Li F, Patsios D, Massey C, Hope A, Keshavjee S, Waddell T, Bezjak A, Shepherd F, De Perrot M, Pierre A, Yasufuku K, Cypel M. O-033 * PATIENTS WITH STAGE IIIA (N2) NON-SMALL-CELL LUNG CANCER SELECTED FOR NEOADJUVANT CHEMORADIATION AND SURGERY HAVE IMPROVED SURVIVAL COMPARED TO PATIENTS TREATED WITH DEFINITIVE CHEMORADIATION. Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu167.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Pawel JV, Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Shepherd F, Spigel D, Hirsh V, Sequist L, Shuster D, Zahir H, Wang Q, Schwartz B, Roemeling RV, Sandler AB. Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC). Pneumologie 2014. [DOI: 10.1055/s-0034-1367776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
43
|
Pawel JV, Jotte R, Spigel DR, Socinski MA, O'Brien MER, Paschold E, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schuette W, Lorigan P, Reck M, Domine M, Shepherd F, McNally R, Renschler M. Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC). Pneumologie 2012. [DOI: 10.1055/s-0032-1302561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Hope A, Giuliani M, Ma C, Bezjak A, Sun A, Brade A, Cho B, Leighl N, Shepherd F, Lindsay P. Dosimetric and Clinical Parameters Contributing to Esophagitis and Radiation Pneumonitis following Treatment for Small-cell Lung Carcinoma. Int J Radiat Oncol Biol Phys 2009. [DOI: 10.1016/j.ijrobp.2009.07.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
45
|
Vincent MD, Butts C, Seymour L, Ding K, Graham B, Twumasi-Ankrah P, Gandara D, Schiller J, Green M, Shepherd F. Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7501] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7501 Background: JBR.10 was one of a number of phase III trials that established adjuvant cisplatin based chemotherapy as a recommended treatment in completely resected NSCLC . Long-term follow-up of these trials is important to document persistent benefit and potential late toxicities of adjuvant therapy. We report the updated survival data for JBR.10 with more than 9 years median follow up. Methods: Patients with completely resected stage IB (T2N0) or II (T1–2N1) NSCLC were randomized to receive 4 cycles of vinorelbine/cisplatin or observation.. Kaplan-Meier curves were generated for overall (OS) and disease specific survival (DSS). Log-rank test was used to compare survival distribution and to test cause specific hazard. For the competing risk analysis, the Gray test was used to test the difference in cause specific incidences. All efficacy analyses were done on an ITT basis. Results: 482 patients were randomized. Data cut-off for this update was July 2008. Median follow-up is 9.3 years (3.2–13.8 y). 12 patients were lost to follow up, a median 4.9 years from randomization (1.5–12 years). 271 deaths have occurred, 73% due to lung cancer or its treatment. Survival analysis continues to show a benefit for chemotherapy: HR .78 (CI .61-.99, p=.04). The benefit appears to be confined to N1 patients: median OS 6.8 y versus 3.6 y, HR .68 (CI .5-.92, p=.01). N0 patients did not appear to benefit: HR 1.03 (CI .7–1.52, p=.87). Chemotherapy significantly prolonged DSS, HR.73 (CI .55-.97, p=.03) Competing risk analysis showed observation to be associated with significantly higher risk of death from lung cancer (p=.02) with no difference in incidences of death from other causes between arms (p=.62). Conclusions: Prolonged follow-up of patients in the JBR.10 trial continues to show a benefit in survival for adjuvant chemotherapy. This benefit appears to be confined to N1 patients. There was no increase in death from other causes in the chemotherapy arm. [Table: see text]
Collapse
Affiliation(s)
- M. D. Vincent
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - C. Butts
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - L. Seymour
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - K. Ding
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - B. Graham
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - P. Twumasi-Ankrah
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - D. Gandara
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - J. Schiller
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - M. Green
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| | - F. Shepherd
- London Regional Cancer Program, London, ON, Canada; Cross Cancer Centre, Edmonton, AB, Canada; NCIC Clinical Trials Group, Kingston, ON, Canada; UC Davis Cancer Centre, Sacremento, CA; Simmons Comprehensive Cancer Center, Dallas, TX; NMCR, Atlanta, GA; Princess Margaret Hospital, Toronto, ON, Canada
| |
Collapse
|
46
|
Goss GD, Addison C, Shepherd F, Seymour L, LeMaitre A, Ding K. TGF-α and amphiregulin levels in non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) BR.21. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11023 Background: In BR.21, erlotinib prolonged survival of previously treated NSCLC pts. We examined the predictive/ prognostic effects of the EGFR ligands, TGFa and amphiregulin(Am). Methods: Plasma was collected prior to treatment in consenting pts. TGFa and Am were analyzed by ELISA (R&D Systems). Samples were blinded, measured in duplicate and ligand concentrations determined following interpolation of a standard curve generated from known quantities of recombinant proteins. Sensitivity was ∼3pg/ml. Cutoff points for TGFa were <10 (low) and ≥10 (high); for Am <1.5 (low) vs 1.5–10 (intermediate) vs >10 (high). Standard statistical methods were used to correlate biomarker data with baseline characteristics and outcomes. Results: In 731 randomized pts, 539 were evaluable for both markers; there was a significant interaction (p=0.03) between the evaluable and inevaluable cohorts (erlotinib benefit favoring the evaluable cohort); evaluable pts were more likely to be male, > 60 and to have EGFR amplification. Baseline high TGFa was associated with poorer ECOG PS (p=0.03) while high Am was associated with worse PS (p<0.0001), anemia (p<0.0001), non response to prior therapies (p=0.01) and no-prior platinum therapy (p=0.02). Although TGFa was not prognostic for OS (HR=1.0, p=0.99), high Am was (HR: Middle vs low: 0.94, 95% C.I 0.49 -1.81; high vs.low: 2.04, 95% C.I 1.43 - 2.91; p=0.0002). High TGFa was a poor prognostic factor for PFS (HR 1.4, p=0.07) as was elevated Am (HR: Middle vs low: 1.02, 95% C.I 0.56 -1.85; high vs. low: 1.67, 95% C.I 1.19 - 2.35, p=0.01). In multivariate analyses including both ligands, high Am remained prognostic, but neither ligand was predictive. Conclusions: High levels of baseline Am appears to be a poor prognostic factor, while low levels of TGFa showed a trend to predict benefit from erlotinib in univariate analyses. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- G. D. Goss
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Health Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute of Canada, Kingston, ON, Canada
| | - C. Addison
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Health Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute of Canada, Kingston, ON, Canada
| | - F. Shepherd
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Health Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute of Canada, Kingston, ON, Canada
| | - L. Seymour
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Health Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute of Canada, Kingston, ON, Canada
| | - A. LeMaitre
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Health Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute of Canada, Kingston, ON, Canada
| | - K. Ding
- The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Health Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; National Cancer Institute of Canada, Kingston, ON, Canada
| |
Collapse
|
47
|
Soria J, Felip E, Herbst R, Hannah N, laurie S, Armand J, Shepherd F, Berman D. 392 POSTER A phase I/II multicenter trial of BMS-690514, an ErbB-VEGFR inhibitor, in patients with advanced NSCLC who are erlotinib naive or previously treated with erlotinib. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72326-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
48
|
Brade A, Bezjak A, MacRae R, Laurie S, Pond G, Afinec A, Iscoe N, Shepherd F. Concurrent Pemetrexed/Cisplatin/Radiation for Unresectable Stage IIIA/B Non-Small Cell Lung Cancer: A Phase I/II Study. Int J Radiat Oncol Biol Phys 2007. [DOI: 10.1016/j.ijrobp.2007.07.1698] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
49
|
Brade A, Bezjak A, MacRae R, Laurie S, Pond G, Afinec A, Iscoe N, Shepherd F. 6550 POSTER A phase I study of concurrent pemetrexed/cisplatin/radiation for unresectable stage IIIA/B non-small cell lung cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71378-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
50
|
Shepherd F, Hasan B, Hicks L, Cheung M, Ding K, Leighl N, Winton T, Seymour L. 6516 ORAL Venous thromboembolism (VTE) and non-small cell lung cancer (NSCLC): a pooled analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trials. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71344-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|